Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease;Epstein-Barr-virus-gerelateerde lymfomen bij patiënten met inflammatoire darmziekte

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 33, 2005, Pages 1859-1863

  Juffermans, N P ^a,b   Jager, A ^a,c   Kersten, M J ^a   Van Oers, M H ^a   Hommes, D W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CROHN DISEASE; ENTERITIS; EPSTEIN BARR VIRUS; HEPATOSPLENOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LYMPHOMA; MALE; MULTIPLE ORGAN FAILURE; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PANCYTOPENIA; PROCTOCOLECTOMY; TREATMENT WITHDRAWAL; ULCERATIVE COLITIS; VIRUS DETECTION;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 23844553072     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pearson DC, May GR, Pick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. Ann Intern Med 1995;123:132-42.
2. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-6.
3. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
4. Dayharsh GA, Loftus jr EV, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-7.
5. Posthuma EF, Westendorp RG, Sluys Veer A van der, Kluin-Nelemans JC, Kluin PM, Lamers CB. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut 1995;36:311-3.
6. Hsiao CH, Kao HL, Lin MC, Su IJ. Ulcerative colon T-cell lymphoma: an unusual entity mimicking Crohn's disease and may be associated with fulminant hemophagocytosis. Hepatogastroenterology 2002;49:950-4.
7. Greenstein AJ, Mullin GE, Strauchen JA, Heimann T, Janowitz HD, Aufses jr AH, et al. Lymphoma in inflammatory bowel disease. Cancer 1992;69:1119-23.
8. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 1994;107:1675-9.
9. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62.
10. Farrell RJ, Ang Y, Kileen P, O'Briain DS, Kelleher D, Keeling PW, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000;47:514-9.
11. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
12. Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-9.
13. Arseneau KO, Stukenborg GJ, Connors jr AF, Cominelli F. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm Bowel Dis 2001;7:106-12.
14. Loftus jr EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000;95:2308-12.
15. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004;350:1328-37.
16. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-12.
17. Sataline LR, Mosley EM, Kirkham W. Ulcerative colitis complicated by colonic lymphoma. Gastroenterology 1962;44:342-7.
18. Lenzen R, Borchard F, Lübke H, Strohmeyer G. Colitis ulcerosa complicated by malignant lymphoma: case report and analysis of published work. Gut 1995;36:306-10.
19. Larvol L, Soule JC, le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994;331:883-4.
20. Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003;17:417-22.
21. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000;118:1018-24.
22. Sinha A, Velangi S, Natarajan S. Non-Hodgkin's lymphoma following treatment of atopic eczema with cyclosporin A. Acta Derm Venereol 2004;84:327-8.
23. Lim IG, Bertouch JV. Remission of lymphoma after drug withdrawal in rheumatoid arthritis. Med J Aust 2002;177:500-1.
24. Ogata M, Kikuchi H, Ono K, Ohtsuka E, Gamachi A, Kashima K, et al. Spontaneous remission of Epstein-Barr virus-negative non-Hodgkin's lymphoma after withdrawal of cyclosporine in a patient with refractory anemia. Int J Hematol 2004;79:161-4.
25. Baird RD, Zyl-Smit RN van, Dilke T, Scott SE, Rassam SMB. Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. Br J Haematol 2002;118:567-8.
26. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-25.
27. Esser JW van, Holt B van der, Meijer E, Niesters HG, Trenschel R, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-8.
28. Verschuuren EA, Stevens S, Pronk I, Bij W van der, Harmsen MC, The TH, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in lung transplant patients. J Heart Lung Transplant 2001;20:199-200.